PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 15, 2026iScience0 citationsOpen Access

Initial biomarker testing strategies and clinical outcomes in advanced non-small cell lung cancer

View Full Paper
MIMasaki IshidaKyoto Prefectural University of MedicineTYTadaaki YamadaKyoto Prefectural University of MedicineYGYasuhiro GotoFujita Health University

Key Points

Key points are not available for this paper at this time.

Abstract

mutations. Our results support further optimization of multiplex assays and evaluation of sequential testing strategies for patients without detected driver oncogenes on initial testing.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ishida et al. (2026) studied this question.

synapsesocial.com/papers/6a199a2a54bb2bac6ef64539https://doi.org/10.1016/j.isci.2026.115966
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non‐small cell lung cancer2024 · 20 citations
  2. 2World Medical Association Declaration of Helsinki2013 · 30,680 citations
  3. 3Genetic Heterogeneity of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cell Lines Revealed by a Rapid and Sensitive Detection System, the Peptide Nucleic Acid-Locked Nucleic Acid PCR Clamp2005 · 511 citations
  4. 4Multiplex gene‐panel testing for lung cancer patients2020 · 61 citations
  5. 5The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group2011 · 227 citations